AEON Biopharma Files 10-Q for Q1 2025
Ticker: AEON · Form: 10-Q · Filed: May 14, 2025 · CIK: 1837607
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials
TL;DR
AEON Biopharma 10-Q filed. Financials updated for Q1 2025.
AI Summary
AEON Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Priveterra Acquisition Corp., is in the pharmaceutical preparations industry. Key financial data points related to warrants and accrued liabilities are included in the filing.
Why It Matters
This filing provides investors with an update on AEON Biopharma's financial position and operational details for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, AEON Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 13890 — Other Accrued Liabilities Current (Represents current liabilities that are not otherwise classified.)
Key Players & Entities
- AEON Biopharma, Inc. (company) — Filer of the 10-Q
- Priveterra Acquisition Corp. (company) — Former name of AEON Biopharma, Inc.
- 20250331 (date) — End of reporting period
- 20250514 (date) — Filing date
- 13890 (dollar_amount) — Value related to Other Accrued Liabilities Current
FAQ
What is the primary business of AEON Biopharma, Inc.?
AEON Biopharma, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What was the reporting period for this 10-Q filing?
The reporting period was for the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 14, 2025.
What was AEON Biopharma's former name?
AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp.
What is the reported value for 'Other Accrued Liabilities Current'?
The value reported for 'Other Accrued Liabilities Current' is 13890.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding AEON Biopharma, Inc. (AEON).